Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 106,113

Document Document Title
WO/2015/086789A1
The invention relates to modified sweet whey protein (MSWP) for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of MSWP for promoting development of t...  
WO/2015/087017A1
The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a degree of molar substitution (MS) of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can b...  
WO/2015/089416A1
Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R...  
WO/2015/085860A1
Disclosed are a heterocyclic hydroxamic acid compound having a general formula I, and pharmaceutically acceptable acid or alkali salts or stereoisomers thereof. The present compound and pharmaceutically acceptable salts thereof effective...  
WO/2015/087853A1
Provided are: a crystal form of (-)-(2-{[3-(5-fluoropyridin-2-yl)-1H-pyrazol-1-yl]methyl}-1, 3-oxazinan-3-yl)[5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]me thanone, said crystal form being stable in the environment of usage thereof as a me...  
WO/2015/088915A1
Methods and compositions are provided for treating a subject for aging-associated conditions, e.g., cognitive impairment conditions. Aspects of the methods include administering a young plasma-comprising blood product to an individual in...  
WO/2015/087926A1
A laminate-type patch which is provided with a support layer, a drug reservoir layer and a pressure-sensitive adhesive layer, wherein: the drug reservoir layer contains at least one drug selected from the group consisting of rivastigmine...  
WO/2015/087993A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is a novel compound or a pharmaceutically acceptable salt thereof which has an antagonistic activity on orexin (OX) receptors and is therefore useful for...  
WO/2015/089327A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.  
WO/2015/086836A1
The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising a least the said derivative, which is a dopamine D3 receptor antagonist, for their use for the treatment of autism spectrum di...  
WO/2015/087016A1
The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be t...  
WO/2015/089420A1
A controlled release dosage form containing monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomcthyl fumarate,...  
WO/2015/088273A1
The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. M...  
WO/2015/085739A1
A multilayer solid pharmaceutical dosage form, comprising a core having active ingredients, a first layer of sustained release coating covering the core, a drug layer having active ingredients and covering the first layer of sustained re...  
WO/2015/089368A3
The invention relates to iRNA, e.g., double- stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such i...  
WO/2015/089349A1
This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compoun...  
WO/2015/088706A1
A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition comprising at least about 0.08 g/100 kcal of stearidonic acid.  
WO/2015/088286A1
The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases, containing a stem cell-derived exosome as an active ingredient. The stem cell-derived exosome according to the present invention has rem...  
WO/2015/086866A1
The invention relates to the use of compounds of the 12-deoxyphorbol family or a pharmacologically active salt of said compounds, for stimulating the proliferation of neural precursors or neural stem cells in a culture. The invention als...  
WO/2015/087927A1
A patch which is provided with a patch member and a cover member, wherein: the patch member is provided with a support layer and a drug reservoir layer which is laminated on one surface of the support layer and which contains both a drug...  
WO/2015/086719A1
The present invention relates generally to supporting the optimal development of children through nutrition and cognitive exercise. In particular, the present invention relates to a growing-up milk composition comprising per daily dose a...  
WO/2015/085909A1
Provided in the present invention is a aminopyrimidine heterocyclic compound with adenosine receptor antagonist activity, comprising the compound and pharmaceutically acceptable salts, various isotopes, isomers and crystal structures the...  
WO/2015/083750A1
Provided is a composition for activating neuropoiesis or neuron proliferation. In one or more embodiments, the composition contains, as the active ingredient, a compound having a DYRK inhibiting ability, a prodrug thereof, or a pharmaceu...  
WO/2015/083816A1
 Provided is a new NK3 receptor selective ligand which is expected to have high activity and high selectivity, and to act in a sustained manner in vivo. A compound expressed by formula (I) X1 - A2 - A3 - X4 - X5 - Met - NH2 [the symb...  
WO/2015/083736A1
 Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method f...  
WO/2015/083094A1
The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparati...  
WO/2015/082590A3
The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel medicaments, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, o...  
WO/2015/082533A1
The present invention relates to compounds according to Formula I: Wherein: A11 - A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(1-6)alky...  
WO/2015/085077A1
Methods of achieving sustained memory improvements and sustained improvement in learning abilities in an infant are provided. The methods comprise administering an effective amount of sialic acid to an infant or a preterm infant until at...  
WO/2015/083129A1
There are described derivatives of gamma-hydroxybutyric acid (GHB), their preparation and their use as GHB pro drugs in the treatment of ethanol addiction. In particular, the derivatives of gamma-hydroxybutyric acid (GHB) have formula (I).  
WO/2015/082357A1
The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the ...  
WO/2015/085192A1
A preparation for treatment and/or prevention of seizures comprising a non-mammalian derived mixture of serine glycerophospholipids (PS) conjugates, wherein the mixture comprises (a) Eicosapentaenoic acid (EPA) conjugated to PS and (b) D...  
WO/2015/082370A1
The present invention provides processes to manufacture substituted l-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b- tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the inven...  
WO/2015/083070A1
The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2- yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2 -yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compo...  
WO/2015/083179A1
A process suitable for adoption to large scale manufacture of 1-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the sy...  
WO/2015/084908A1
The present invention relates to the field of stem cells. More specifically, the present invention provides methods and compositions useful for the highly efficient conversion of human stem cells to lineage-specific neurons. In a specifi...  
WO/2015/083071A1
The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1 H-benzo[d]imidazol- 2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol -2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, phar...  
WO/2015/082932A1
The present invention relates to opioid compounds, especially to C14 esters and ethers of naltrexone and analogues thereof. The present invention also relates to compositions, methods and medical uses that employ such compounds. More spe...  
WO/2015/081822A1
Disclosed are a 3-furyl-2-cyano-2-acrylamide derivative with epidermal growth factor receptor (EGFR) inhibitory activity and pharmaceutical acceptable salt thereof, together with preparation method therefor, pharmaceutical composition co...  
WO/2015/081850A1
Disclosed is an intravitreal injection drug delivery system for mouse nerve growth factor (mNGF), the system being characterized by comprising the mNGF and an ultrasonic contrast agent. Also disclosed is an application of the intravitrea...  
WO/2015/084161A1
Composition comprising a uridine source, an omega-3 PUFA for improving coordination, balance, grip strength or fine motor skills. The invention is directed to a combination of a uridine source and an omega-3-polyunsaturated fatty acid ha...  
WO/2015/083871A1
The present invention relates to a composition containing osmotin as an active ingredient for improving cognitive function. More specifically, in an Aβ-induced neurodegenerative mouse model administered with osmotin, Aβ-induced memory ...  
WO/2015/077905A1
Disclosed are compounds of Formula (A-a), or a salt thereof, Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also desc...  
WO/2015/078935A1
The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for parti...  
WO/2015/081085A3
The present disclosure provides methods for treating a tauopathy (e.g., an acute tauopathy) in an individual by administering an anti-Tau antibody to the individual. Also provided are methods of treating traumatic brain injury and method...  
WO/2015/079459A1
Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmac...  
WO/2015/079390A1
The invention relates to 3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone (T I F) and achillolid A in prevention or treatment of Alzheimer's disease as well as other neurodegenerative diseases such as Parkinson's disease, Amyotrophic Lateral S...  
WO/2015/079224A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions conta...  
WO/2015/078374A1
The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as desc...  
WO/2015/078836A1
The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before.  

Matches 201 - 250 out of 106,113